• Home
  • Mail
  • News
  • Finance
  • Sports
  • Entertainment
  • Search
  • Mobile
  • More
Yahoo
    • Skip to Navigation
    • Skip to Main Content
    • Skip to Related Content
    • Mail
    Advertisement

    University Lab Partners selected by CIMIT to partner in their project to support the NIH RADx initiative

    PR Newswire•October 21, 2020

    IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- University Lab Partners has been selected by the Boston-based Consortia for Improving Medicine with Innovation & Technology (CIMIT) to partner in their project to support the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, which is working to accelerate the commercialization and deployment of new COVID-19 testing technologies. The goal of RADxSM is to make millions of tests per week available to Americans, particularly those most vulnerable to and/or disproportionately impacted by COVID-19, and having even more tests available in time for the 2020–2021 flu season.

    University Lab Partners selected by CIMIT to partner in their project to support the NIH RADx initiative.

    About ULP:
    University Lab Partners is a Southern California based biotech/medtech incubator focused on accelerating the commercialization of innovative technologies. University Lab Partners is an independent, non-profit entity located adjacent to University of California – Irvine that actively brings together world-class academic and medical institutions, medical device and diagnostic testing industry partners, and investment community members from the Region to accelerate the launch of new companies, products and the creation of new jobs.

    About CIMIT:
    CIMIT was formed in 1998 as a "center without walls," linking four leading academic research centers in the greater Boston area. It now includes 13 of Boston's strongest academic medical centers, universities, and a growing network of national and international affiliates. Starting from a foundation in medical devices, diagnostics, and procedures, the scope has grown to address the full spectrum of medical innovation including e-health, drugs, and biologics

    About the NIH RADx initiative:
    NIH launched the Rapid Acceleration of Diagnostics (RADxSM) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The initiative leverages the existing NIH Point-of-Care Technology Research Network. The RADx initiative partners with federal agencies, including the Office of the Assistant Secretary of Health, Department of Defense, the Biomedical Advanced Research and Development Authority, and U.S. Food and Drug Administration. Learn more about the RADx initiative and its programs: https://www.nih.gov/radx.

     

    Cision
    Cision

    View original content:http://www.prnewswire.com/news-releases/university-lab-partners-selected-by-cimit-to-partner-in-their-project-to-support-the-nih-radx-initiative-301157404.html

    SOURCE University Lab Partners

    Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting.

    What to Read Next

    • This Is What It Means If You Don't Pee Enough, According to Science

      Best Life
    • Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update

      GlobeNewswire
    • New Data Shows Nurses and Their Families are at Significantly Higher Risk for COVID-19 Infection and Hospitalization Vs. General Public

      GlobeNewswire
    • AzurRx BioPharma Announces Formation of Scientific Advisory Board

      GlobeNewswire
    • Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020

      GlobeNewswire
    • Trump lawyer Rudy Giuliani caught in compromising position with young actress in Borat film 'gotcha'

      The Telegraph
    • Why 780 retired generals and former national security leaders spoke out against Trump

      Yahoo News
    • Cloud API Market Research Report by Type, by Enterprise Size, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19

      GlobeNewswire
    • Rudy Giuliani Caught On Camera Appearing To Touch Genitals During ‘Borat’ Prank

      HuffPost
    • Lawyers say they can't find the parents of 545 migrant children separated by Trump administration

      NBC News
    • Romney: 'I did not vote for President Trump'

      Yahoo News
    • AstraZeneca COVID-19 vaccine trial continues despite Brazilian volunteer death

      Yahoo News Video
    • Top Healthcare Stocks for November 2020

      Investopedia
    • Mouthwash could 'inactivate' human coronaviruses that cause infections like the common cold

      Yahoo Life
    • Intel Officers 'Terrified' Of Briefing Trump On Russia Because He Would 'Explode': Report

      HuffPost
    • 'Back to the Future' Day: Never-told stories about Eric Stoltz's firing, A-list actors who auditioned and the Biff Tannen-Donald Trump connection

      Yahoo Movies
    • Trump has sparked a shift in how some conservatives talk and think about abortion

      Yahoo News
    • California boat owners faulted for fire that killed 34 people

      Yahoo News Video
    • 3D Cell Culture Market Size is Estimated To Garner USD 3,721.68 Million By 2027 - Valuates Reports

      PR Newswire
    • Nicki Minaj Shares First Photo of Her Baby Boy

      Elle
    • Fantasy Football Trade Analyzer: Why it's the perfect time to explore dealing red-hot Chase Claypool

      4for4
    • 'We will come after you': Voters report personalized emails pressuring them to vote for Donald Trump

      USA TODAY
    • Man accused of threatening Biden, Harris in letter to neighbor

      Yahoo News Video
    • Cephalosporin Drugs Market Research Report by Generation of Cephalosporin, by Drug Administration, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

      PR Newswire
    • Yahoo News Network
    • Help
    • Privacy (Updated)
    • Do Not Sell My Personal Information
    • Suggestions
    • About our Ads
    • Terms (Updated)
    • Sitemap